Synapse - Michael Mauro

Results (276)

AIM4CML trial in progress: A phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutations

Meeting Abstract

Levy, M. Y.; Mauro, M. J.; Issa, G. C.; Andorsky, D.; Tomassetti, S.; Maegawa, R.; Shrestha, A.; Deininger, M.
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy

Journal Article

Cortes, J. E.; Kantarjian, H. M.; Mauro, M. J.; An, F.; Nick, S.; Leip, E.; Gambacorti-Passerini, C.; Brümmendorf, T. H.
European Journal of Haematology (2021)

Fulltext@MSK | Save

Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial

Journal Article

Atallah, E.; Schiffer, C. A.; Radich, J. P.; Weinfurt, K. P.; Zhang, M. J.; Pinilla-Ibarz, J.; Kota, V.; Larson, R. A.; Moore, J. O.; Mauro, M. J.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Myeloid/lymphoid neoplasms with eosinophilia/basophilia and ETV6-ABL1 fusion: Cell-of-origin and response to tyrosine kinase inhibition

Research Letter

Yao, J.; Xu, L.; Aypar, U.; Meyerson, H. J.; Londono, D.; Gao, Q.; Baik, J.; Dietz, J.; Benayed, R.; Sigler, A.; more...
Haematologica (2021)

Fulltext@MSK | Save

COVID-19 in patients (pts) with chronic myeloid leukemia (CML): Results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study

Meeting Abstract

Rea, D.; Mauro, M. J.; Cortes, J. E.; Jiang, Q.; Pagnano, K. B.; Ongondi, M.; Kok, C. H.; Evans, N.; Hughes, T. P.; International CML Foundation
Blood (2020)

Fulltext@MSK | Save

Impact of COVID19 pandemic on an international MPN patient population: Survey results from 1560 MPN patients

Meeting Abstract

Palmer, J. M.; Mead-Harvey, C.; Harrison, C.; Dueck, A. C.; Eckert, R.; Kosiorek, H. E.; Muxi, P.; Pemmaraju, N.; Arguelles, G. R.; Vannucchi, A. M.; more...
Blood (2020)

Fulltext@MSK | Save

Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States: Baseline and six-month follow-up results from a prospective real-world observational study

Meeting Abstract

Mauro, M. J.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; Dakhil, S. R.; DeGutis, I.; Tabano, D.; Khan, W.; Moslehi, J. J.
Blood (2020)

Fulltext@MSK | Save

Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): Analyses based on PACE and OPTIC

Meeting Abstract

Kantarjian, H. M.; Deininger, M. W.; Abruzzese, E.; Apperley, J.; Cortes, J. E.; Chuah, C.; DeAngelo, D. J.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
Blood (2020)

Fulltext@MSK | Save

Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib